A5045575537- Heart Failure Treatment and Management
- Mechanical Circulatory Support Devices
- Cardiac pacing and defibrillation studies
- Cardiac Structural Anomalies and Repair
- Cardiovascular Function and Risk Factors
- Amyloidosis: Diagnosis, Treatment, Outcomes
- Viral Infections and Immunology Research
- Cardiac Valve Diseases and Treatments
- Transplantation: Methods and Outcomes
- Potassium and Related Disorders
- Cardiac Health and Mental Health
- Parathyroid Disorders and Treatments
- Electronic Health Records Systems
- Nuclear Structure and Function
- Pericarditis and Cardiac Tamponade
- RNA Research and Splicing
- Eosinophilic Disorders and Syndromes
- Cardiac electrophysiology and arrhythmias
- Cardiovascular Effects of Exercise
- Cardiac Arrest and Resuscitation
- Medication Adherence and Compliance
- Bipolar Disorder and Treatment
- Infective Endocarditis Diagnosis and Management
- Metabolism and Genetic Disorders
- Machine Learning in Healthcare
Innsbruck Medical University
2016-2025
Universität Innsbruck
2015-2025
Tirol Kliniken
2024
Research Center of Neurology
2023
Orion Corporation (Finland)
2019-2020
University Hospital Innsbruck
2020
Universitätskliniken Salzburg
2015
Ordensklinikum Linz Barmherzige Schwestern
1997
Abstract Aims Anaemia and iron deficiency (ID) are frequently found in patients with chronic heart failure (CHF) associated adverse outcome. However, it is unclear whether absolute [transferrin saturation (TSAT) <20%, ferritin <100 μg/L] or inflammation‐driven functional ID (TSAT >100 μg/L) without anaemia had similar different consequences for such patients. Methods results Within this retrospective cohort study, 2223 (1601 men 622 women) CHF, referred to our department, between...
Inotropes aim at increasing cardiac output by enhancing contractility. They constitute the third pharmacological pillar in treatment of patients with decompensated heart failure, other two being diuretics and vasodilators. Three classes parenterally administered inotropes are currently indicated for (i) beta adrenergic agonists, including dopamine dobutamine also catecholamines epinephrine norepinephrine, (ii) phosphodiesterase III inhibitor milrinone (iii) calcium sensitizer levosimendan....
BackgroundThe intravenous inodilator levosimendan was developed for the treatment of patients with acutely decompensated heart failure. In last decade scientific and clinical interest has arisen its repetitive or intermittent use in advanced chronic, but not necessarily decompensated, Recent studies have suggested long-lasting favourable effects when administered repetitively, terms haemodynamic parameters, neurohormonal inflammatory markers, outcomes. The existing data, however, requires...
Abstract Hospitalization for acute heart failure (HF) is associated with a substantial morbidity burden and healthcare costs an increased mortality risk. However, few if any major medical innovations have been witnessed in this area recent times. Levosimendan first‐in‐class calcium sensitizer potassium channel opener indicated the management of HF. Experience several clinical studies has that administration intravenous levosimendan intermittent cycles may reduce hospitalization rates...
The prevalence and significance of cardiac amyloidosis have been considerably underestimated in the past; however, number patients diagnosed with has increased significantly recently due to growing awareness disease, improved diagnostic capabilities demographic trends. Specific therapies that improve patient prognosis become available for certain types amyloidosis. Thus, earliest possible referral suspicion an experienced center is crucial ensure rapid diagnosis, early initiation treatment,...
The LeoDOR trial explored the efficacy and safety of intermittent levosimendan therapy in vulnerable phase following a hospitalization for acute heart failure (HF).In this prospective multicentre, double-blind, two-armed trial, patients with advanced HF were randomized 2:1 at end an index to or matching placebo 12 weeks. All had left ventricular ejection fraction (LVEF) ≤30% during hospitalization. Levosimendan was administered according centre preference either as 6 h infusion rate 0.2...
Abstract Aims Iron is essential to maintain cellular energy metabolism in the myocardium. Impaired iron availability negatively affects myocardial physiology and can aggravate heart failure (HF). deficiency (ID) frequently found patients with acute chronic HF (AHF, CHF) associated clinical outcome. The aim of this analysis was assess true ID prevalence on basis different definitions. Methods We performed a retrospective 329 AHF 613 CHF patients, recruited between 02/2021 05/2022 at Innsbruck...
Background: Heart failure is a major health problem associated with frequent hospital admissions. HerzMobil Tirol multidisciplinary postdischarge disease management program for heart patients to improve quality of life, prevent readmission, and reduce mortality care costs. It uses telemonitoring system that incorporated into network specialized nurses, physicians, hospitals. Patients are equipped mobile phone, weighing scale, blood pressure rate monitor daily acquisition transmission data on...
In general, a mitochondrial disorder is diagnosed on the basis of symptom combinations and confirmed by genetic findings. However, patients carrying m.3243A>G mutation in tRNA leucine 1 (MT-TL1) do not always meet all proposed criteria for most frequently encountered syndrome "MELAS," an acronym Mitochondrial Encephalomyopathy, Lactic Acidosis, at least one Stroke-like episode. We here present various phenotypic characteristics with particular focus cardiac manifestations.We followed nine (1...
Background Mutations in the LMNA gene are a common cause (6–8%) of dilated cardiomyopathy (DCM) leading to heart failure, growing health care problem worldwide. The premature aging disease Hutchinson-Gilford syndrome (HGPS) is also caused by defined mutations resulting activation cryptic splice donor site defective truncated prelamin A protein called progerin. Low levels progerin expressed healthy individuals associated with ageing. Here, we aimed address role cardiomyopathy. Methods and...
Inotropes may be an appropriate treatment for patients with advanced heart failure (AdHF) who remain highly symptomatic despite optimized standard therapies. Objectives inotrope use in these situations include relief of symptoms and improvement quality life, reduction unplanned hospitalizations the costs associated such episodes. All goals must attained without compromising survival. Encouraging findings intermittent cycles intravenous levosimendan have emerged from a range exploratory...
The burgeoning domain of telehealth has witnessed substantial transformation through the advent advanced technologies such as Large Language Models (LLMs). This study examines integration LLMs in heart failure management, with a focus on HerzMobil pioneering program. technical underpinnings LLMs, their current applications medical field, and potential to enhance services, have been explored. paper highlights benefits patient interaction, clinical documentation, decision-making processes....
Introduction The potential for secondary use of health data to improve healthcare is currently not fully exploited. Health largely kept in isolated silos and key infrastructure aggregate these into standardized bodies knowledge underdeveloped. We describe the development, implementation, evaluation a federated facilitate versatile based on Data Space nodes. Materials methods Our proposed nodes are self-contained units that digest through an extract-transform-load framework pseudonymizes...